Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Mr. Hiroyuki Minoura, Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Japan

Mr. Hiroyuki Minoura is a dedicated and accomplished researcher in computational biology and bioinformatics 🧬. With a solid academic foundation in science and technology 🎓, he has contributed to multiple research projects focused on systems pharmacology, precision medicine, and data-driven modeling 🧠. His work is widely cited in top scientific databases such as Scopus and Google Scholar 📊, and he has published in several high-impact journals 📝. Mr. Minoura is known for his interdisciplinary collaborations 🤝 and commitment to innovation in healthcare solutions. His research continues to bridge complex biological data and clinical applications for a better tomorrow.

Publication Profile 

Google Scholar

Education

Mr. Hiroyuki Minoura 🎓 has built a strong academic and professional foundation rooted in research and innovation. With a solid educational background and years of experience in scientific study, he has contributed meaningfully to his field. His commitment to advancing knowledge is reflected in his work on cutting-edge research projects and industry collaborations. 🧪 Through consistent scholarly output and a keen focus on impactful solutions, Mr. Minoura has established himself as a promising leader in the research community. 🌍 His achievements not only demonstrate academic excellence but also highlight his potential to drive future advancements in science and technology.

Research and Innovations

Mr. Hiroyuki Minoura 🧠 has made remarkable strides in the realm of research and innovation. With a portfolio that includes numerous completed and ongoing research projects 🔬, he has consistently contributed to scientific progress. His publications in indexed journals 📚 and his registered patents 📄 reflect a commitment to cutting-edge discovery and practical application. Mr. Minoura’s impressive citation index 📈 underscores the influence of his work in the academic community. Additionally, his involvement in industry-sponsored projects 🤝 showcases the relevance and impact of his research beyond academia. His innovative contributions continue to shape advancements across multiple scientific disciplines.

Research Focus

Mr. Hiroyuki Minoura’s research focus lies at the nexus of surgical oncology and gastroenterology, concentrating on upper gastrointestinal malignancies—particularly gastric and esophagogastric junction cancers. 🏥🔬 He investigates appetite‑preserving gastrectomy, safe esophago‑jejunal reconstructions, and molecular crosstalk between cancer‑associated fibroblasts and the TGF‑β pathway, aiming to craft organ‑sparing, patient‑centred therapies. 🍽️🧬 His studies span bench to bedside: from laparoscopic innovations and “parachute” anastomosis techniques 🩺✂️ to translational biomarker discovery for precision medicine. 📊💉 Minoura also evaluates systemic regimens like mFOLFIRINOX for metastatic cases, bridging surgery with chemotherapy. 🚀 His holistic, innovation‑driven approach advances outcomes for complex digestive cancers worldwide patient survival.

Publication Top Notes

Chen Xie | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Chen Xie | Gene Therapy | Best Researcher Award

Assoc. Prof. Dr. Chen Xie, Medical Research Center, the Eighth Affiliated Hospital of Sun Yat-sen University, China

Assoc. Prof. Dr. Chen Xie is a distinguished researcher at the Medical Research Center, Eighth Affiliated Hospital of Sun Yat-Sen University. With a Ph.D. in Biochemical Engineering from Huaqiao University and postdoctoral experience in genetics at Sun Yat-Sen University, his work focuses on inflammation, DNA damage, senescence, and noncoding RNAs. 🧬 He has published eight impactful papers in journals such as Signal Transduct Target Ther, Mol Cell, and Cancer Immunol Res and holds an H-index of 9. 🧪 Dr. Xie is a recipient of multiple national honors and leads NSFC-funded research advancing disease-related molecular mechanisms.

Publication Profile

orcid

Education

Assoc. Prof. Dr. Chen Xie is a dedicated researcher with a strong background in biochemical and genetic sciences. He began his academic journey with a Bachelor’s degree in Bioengineering from Huaqiao University 🎓 (2007–2011), followed by a Master’s in Genetics from Sun Yat-Sen University 🔬 (2011–2014). He earned his Ph.D. in Biochemical Engineering in 2018 🧪. Dr. Xie completed a postdoctoral fellowship at Sun Yat-Sen University (2018–2021), and then served as Assistant Professor (2021–2025). Since March 2025, he has been an Associate Professor at the Medical Research Center, Eighth Affiliated Hospital of Sun Yat-Sen University 🏥, advancing biomedical research.

Experience

Assoc. Prof. Dr. Chen Xie mainly focuses on exploring the intricate relationship between inflammation, DNA damage, cellular senescence, noncoding RNAs, and human diseases 🧬. His impactful research has earned him prestigious honors such as the National Natural Science Foundation of China award, the National Scholarship 🏅, the First Prize Scholarship of Huaqiao University, and the Alumni Scholarship 🎓. Dr. Xie has published 8 influential papers in top-tier journals including Signal Transduction and Targeted Therapy, Molecular Cell, and Cancer Immunology Research 📚. With an H-index of 9, he continues to contribute significantly to biomedical science 🧫.

Awards

Assoc. Prof. Dr. Chen Xie has received several prestigious awards in recognition of his academic excellence and research contributions 🎓. He was honored with a National Scholarship for his outstanding performance and dedication to scientific advancement. During his studies at Huaqiao University, he earned the First Prize Scholarship 🥇, highlighting his exceptional academic achievements. Additionally, he received an Alumni Scholarship, reflecting the strong support and recognition from his academic community 🌟. These accolades underscore Dr. Xie’s commitment to excellence in the fields of biochemical engineering, genetics, and biomedical research 🔬.

Research Focus

Assoc. Prof. Dr. Chen Xie is a leading researcher in the fields of molecular biology, epigenetics, and cellular senescence, with a strong emphasis on mechanisms of vascular and pulmonary aging, DNA damage repair, and RNA modifications (e.g., m6A). 🧬 His work uncovers how factors like GATA6, YTHDC1, and FTO regulate aging, fibrosis, cancer, and immune responses, often via intricate signaling pathways and RNA interactions. 🧠🧫 He contributes significantly to understanding vascular calcification, fibrosis, and glioma biology, advancing targeted therapies. His research bridges cellular aging and precision medicine, making a profound impact on age-related and inflammatory diseases.

Publication Top Notes

The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair

YTHDC1 delays cellular senescence and pulmonary fibrosis by activating ATR in an m6A-independent manner

C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification <i>via</i> PERK-eIF2α-ATF4-CREB3L1 pathway

UBQLN1 deficiency mediates telomere shortening and IPF through interacting with RPA1

Data from FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma

Supplementary Data from FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma

cGAS guards against chromosome end-to-end fusions during mitosis and facilitates replicative senescence

Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7

Xandra Breakefield | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Xandra Breakefield | Gene Therapy | Best Researcher Award

Prof. Dr. Xandra Breakefield, Massachusetts General Hospital/Harvard Medical School, United States

Prof. Dr. Xandra Breakefield is a pioneering geneticist and neuroscientist specializing in gene therapy and extracellular vesicle research. She earned her Ph.D. from Georgetown University and trained at NIH under Nobel Laureate Dr. Marshall Nirenberg. A Harvard Medical School professor and Massachusetts General Hospital researcher, she has made groundbreaking contributions to neurogenetics and dystonia. Recognized with numerous prestigious awards 🏆, including the Mika Salpeter Lifetime Achievement Award, she ranks among the world’s top scientists. A leader in gene and cell therapy, she serves on advisory boards worldwide 🌍, shaping the future of biomedical research.

Publication Profile

orcid

Education

Prof. Dr. Xandra Breakefield 🎓 embarked on her academic journey with an A.B. in Biology from Wilson College (1960-1965), graduating cum laude for her outstanding performance. During this period, she also enriched her knowledge at American University (1964-1965), deepening her expertise in biology 🧬. Her passion for microbial genetics led her to pursue a Ph.D. at Georgetown University (1967-1971), where she specialized in microbial genetics 🦠. This strong educational foundation set the stage for her groundbreaking contributions to the field, establishing her as a distinguished researcher in genetics and molecular biology. 🌟

Professional Experience

Prof. Dr. Xandra Breakefield 🧬 has had an illustrious career in genetics and neurology. She has been a Geneticist at Massachusetts General Hospital’s Radiology Service since 2002 and a Professor of Neurology at Harvard Medical School since 1996. Previously, she held key roles in molecular neurogenetics at Massachusetts General Hospital 🏥 and directed the Division of Molecular Neurogenetics at the Eunice Kennedy Shriver Center. Her academic journey includes faculty positions at Yale University and Georgetown University 📚. Early in her career, she trained under Nobel Laureate Dr. Marshall Nirenberg at NIH, shaping her expertise in biochemical genetics. 🌟

Awards

Prof. Dr. Xandra Breakefield 🧬 has received numerous prestigious awards for her groundbreaking contributions to neuroscience and genetics. She earned the McKnight Neuroscience Development Award (1982-1984) and two Javits Neuroscience Investigator Awards (1985-1992, 1995-2002). She was honored with an Honorary Doctorate from Wilson College (1991) and an Honorary Master’s Degree from Harvard Medical School (1996) 🎓. Recognized globally, she received the Mika Salpeter Lifetime Achievement Award (2013) and the NIH Director’s WALS Speaker Award (2017). Ranked among the Top 1000 Female Scientists in the World (2022, 2024), her work continues to shape modern molecular medicine. 🌟

Research Focus

Prof. Dr. Xandra O. Breakefield focuses on neuroscience, gene therapy, and extracellular vesicles 🧠🧬🩸. Her research explores how extracellular vesicles facilitate cell-to-cell communication and their potential for delivering gene therapies to treat neurological disorders and cancers. She also investigates glioblastoma, a highly aggressive brain tumor, using cortical organoids 🧪🔬 to study cell-state heterogeneity and intercellular transfer. Her work has significant implications for precision medicine and targeted therapies 🎯💊. As a leading expert in the field, she collaborates on innovative projects integrating genomics, bioengineering, and molecular biology to advance treatments for brain diseases.

Publication Top Notes

Extracellular vesicles for the delivery of gene therapy

Data from Glioblastoma Cortical Organoids Recapitulate Cell-State Heterogeneity and Intercellular Transfer

RNA delivery by extracellular vesicles in mammalian cells and its applications

Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression

Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function

Exosome/microvesicle content is altered in leucine‐rich repeat kinase 2 mutant induced pluripotent stem cell‐derived neural cells

Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells